NAD+ dosage & cycles.

Daily dosage and frequency

100 mg of NAD+ once daily for three consecutive days was the schedule used in a 2026 injection pilot. Clinicians administered the doses to separate subcutaneous, intramuscular and intravenous groups. The course total was 300 mg, followed by a seven-day washout and assessment on day 10. This was a small preliminary study reported as a preprint. [1]

The injection pilot included six NAD+ recipients in its subcutaneous group, four in its intramuscular group and five in its intravenous group. The 2019 study included eight NAD+ recipients; the four-day IV series included six. Their amounts remain tied to their routes and supervised study settings. [1] [2] [3]

The nasal spray contains 150 mcg per spray. Its bottle holds 30 mg across 200 sprays. The vial contains 1,000 mg of powder, and the prefilled pen contains 1,500 mg in 3 mL at 500 mg/mL. Product amounts determine the measurement; a treatment schedule also depends on the route and clinical plan. [4]

Reconstituting a 1,000 mg NAD+ vial

The vial contains 1,000 mg of dry NAD+ in a 10 mL container. The container size describes its capacity. The final solution volume determines concentration: 1,000 mg divided by 2 mL is 500 mg/mL; divided by 5 mL, it is 200 mg/mL. [4]

For an injectable preparation, the prescribing clinician or dispensing pharmacy specifies the sterile diluent, final volume and beyond-use date. The concentration examples below show how to measure a chosen amount from that prepared solution.

Preparation and storage: product specifications and general safe-injection guidance. The volume examples are concentration calculations. [4] [5] [8]

Adding more liquid lowers the concentration while keeping the same total 1,000 mg of NAD+. The amount in a measured portion is concentration multiplied by liquid volume: 500 mg/mL × 0.2 mL = 100 mg.

Preparation used in the injection study

The 2026 pilot used 100 mg dissolved in 2 mL of bacteriostatic water, giving 50 mg/mL. It used pharmacy-compounded, single-use doses administered by clinicians. That describes the study preparation. For any other prepared solution, calculate its draw volume from its own concentration. [1]

Subcutaneous injection sites

For prescribed subcutaneous administration, the injection goes into the fatty layer beneath the skin. General medication guidance lists the abdomen, outer upper thigh, and side or back of the upper arm. On the abdomen, stay at least 2 inches, about 5 cm, from the belly button. [6]

Rotate locations and use healthy skin. Avoid areas that are red, swollen, bruised or scarred. Use the needle and technique provided for the prescribed preparation. The graphic shows general subcutaneous locations; intramuscular injections and IV infusions use different techniques.

Timing, morning or evening, and food

The four-day IV series scheduled repeat visits at the same time each day. The injection pilot required an eight-hour fast before clinic visits. These were study procedures linked to treatment visits and assessments. [3] [1]

The studies did not compare morning with evening administration or demonstrate that fasting improves NAD+ benefits. Follow the prescribed timetable and any food or fluid instructions for the specific treatment. The results article covers measured changes and their time points.

NAD+ calculator: milligrams, millilitres and syringe units

Enter the vial total, final solution volume and target amount. The loaded example uses 1,000 mg in 2 mL and a 100 mg target. It gives 500 mg/mL, 0.2 mL and 20 U-100 units.

A U-100 syringe has 100 units per millilitre: 1 unit equals 0.01 mL. At 500 mg/mL, each of those units contains 5 mg of NAD+. At 200 mg/mL, each contains 2 mg. Changing the final solution volume therefore changes the syringe measurement for the same amount.

1 mg = 1,000 mcg. A 100 mg target is 100,000 mcg, and the spray's 150 mcg amount is 0.15 mg. The unit selector preserves the entered amount when switching between mg and mcg. The calculator converts quantities; the prescribed plan supplies the treatment amount.

For example, changing the vial's final volume from 2 mL to 4 mL changes concentration from 500 to 250 mg/mL. The volume containing 100 mg then becomes 0.4 mL, or 40 U-100 units. The total material in the vial remains 1,000 mg.

Daily and weekly totals

The three-day injection schedule totals 300 mg within the first week. It delivers 100 mg on each of three treatment days, followed by days without treatment during the washout. The four-day IV schedule totals 2,000 mg.

For a daily total, multiply the amount per administration by the number given that day. Add the daily totals for the weekly amount. A spray count records product content; it does not assign a dosing frequency or an equivalent injected amount.

Cycle length and time off

The injection pilot used three treatment days, then a seven-day washout. Assessment took place on day 10. The four-day IV series followed participants for 30 days, while the earlier metabolism study used one six-hour infusion. [1] [3] [2]

Treatment days and follow-up days have separate roles: treatment days determine the amount administered, while follow-up measures what happens afterwards. A longer follow-up does not add more doses to the course. Decisions about repeating treatment belong to the clinical plan.

A separate 90-day injection report used nicotinamide riboside, or NR, at 50 or 100 mg three times weekly. NR is a precursor used to make NAD+ in the body. That ingredient-specific schedule belongs to the NR study. [7]

Persistent injection-site irritation or symptoms during treatment should be reviewed before another administration. The NAD+ side-effects article explains the reported reactions and when medical attention is needed.

Pen and nasal spray dosage measurements

Prefilled pen: 500 mg/mL

The pen contains 1,500 mg of NAD+ in 3 mL at 500 mg/mL. It is ready-made liquid and requires no reconstitution. Divide the desired amount in milligrams by 500 to calculate its volume in millilitres. [4]

Operate the pen using its device instructions. Store it capped, refrigerated at 2–8°C and protected from light; do not freeze it. The product comparison includes its preparation, storage and pack details.

Nasal spray: 150 mcg per spray

30 mg per bottle · 200 sprays · 150 mcg per spray. Divide 30 mg by 200 to get 0.15 mg, equivalent to 150 mcg. The spray is already prepared and does not need reconstitution. [4]

Count complete pump actuations and follow the bottle's pump-use instructions. Keep the bottle upright and capped at 2–8°C, protected from light. Do not freeze it.

Total milligrams, vials, pens and sprays

A 1,000 mg vial contains ten 100 mg portions; a 1,500 mg pen contains fifteen. At 50 mg per portion, the totals are twenty and thirty. These are material-yield calculations before transfer losses and priming.

For a planned total, divide the required milligrams by the amount in one product and round up to whole packs. A 300 mg total fits within one 1,000 mg vial or one 1,500 mg pen. A 2,000 mg total requires two of either product by mass.

The nasal bottle contains 200 sprays. That is 100 groups of two sprays or 50 groups of four sprays. One hundred sprays contains 15 mg, half the bottle's 30 mg total. These counts describe quantity rather than calendar duration.

Use the preparation's assigned beyond-use date when planning quantities. The sealed powder's COA retest date is 17 September 2028; an opened or mixed preparation follows its own storage period. [8] Compare the 1,000 mg vial, 1,500 mg pen and 30 mg nasal spray for pack size, preparation and batch testing.